HUTCHMED (China)
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related di...
Latest News
1 day ago · globenewswire.com
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2027 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.
4 days ago · seekingalpha.com
HUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference TranscriptHUTCHMED (China) Limited (HCM) Presents at Deutsche Bank Virtual Investor Conference Transcript
6 days ago · globenewswire.com
Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893's potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen LIONHEART-HCM oHCM Phase 3 enrolling with interim analysis expected in second half of 2027; TRUEHEART-HCM fixed-dose oHCM Phase 2b and NOBLEHEART-HCM Phase 3 in nHCM on track to initiate in first half of 2027 Cash, cash equivalents and investments of $503.5 million; cash runway expected into 2029 SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy ("HCM") and other serious cardiovascular diseases, today reported unaudited financial results for the third quarter ended September 30, 2026, and provided a business update. “BHB-1893 continues to show a consistent, potentially differentiated profile across multiple clinical studies and our mechanistic work,” said Travis Murdoch, M.D.
12 days ago · prnewswire.com
Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO ₂ as the primary endpoint – – STRATUS-HCM on track to start in the fourth quarter of 2026 – BOULDER, Colo., Nov. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced favorable feedback from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for EDG-7500 in symptomatic obstructive and nonobstructive hypertrophic cardiomyopathy (HCM).
12 days ago · globenewswire.com
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia— Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval —
15 days ago · globenewswire.com
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress —
18 days ago · globenewswire.com
Braveheart Bio to Host Webinar – HCM Spotlight: Advancing a Next-Generation Cardiac Myosin Inhibitor – with Key Opinion Leader Discussion on November 6, 2026SAN FRANCISCO, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will host an investor and analyst webinar on Friday, November 6, 2026, from 4:35 p.m. to 6:05 p.m. ET. The event will feature remarks on Braveheart Bio's cardiac myosin inhibitor program and the global clinical development of BHB-1893 in patients with obstructive HCM and non-obstructive HCM from Management and the following speakers:
19 days ago · globenewswire.com
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition — — Eligible for development incentives including 7 years of US market exclusivity upon regulatory approval — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 28, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the US Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (“ITP”), an autoimmune disorder that can lead to increased risk of bleeding.
21 days ago · globenewswire.com
Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung CancerHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on Thursday, November 5, 2026, at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST.
22 days ago · globenewswire.com
HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026— ORPATHYS ® plus TAGRISSO ® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —
Analyst Summary
Add to Watchlist
Select watchlists to add or remove HCM